Previous 10 | Next 10 |
Cowen has initiated shares of Celcuity (CELC +6.2%) with an overweight rating but no price target. The company is developing a companion diagnostic, CELsignia, for breast cancer. CELsignia uses live tumor cells derived from a patient biopsy and measures real-time activity changes in response ...
MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the William Blair Biotech Focus Confe...
Celcuity analyzes live tumor cells for oncogenic pathways. It identifies abnormal oncogenic signaling pathways to detect new treatment options. The company develops targeted therapies for cancer patients. For further details see: Celcuity: Nipping The Oncogenic Bud
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite (AMST) +22%.Global Internet of Peopl...
Shares of Celcuity (NASDAQ: CELC) were crashing 19.3% lower as of 10:54 a.m. EDT on Tuesday. The big decline came after the biotechnology company announced the pricing of a secondary stock offering. It's not surprising in the least that the biotech stock fell hard today. Cel...
Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifescience...
DiaMedica Therapeutics DMAC -27% after announcing mixed results for kidney disease therapy in mid-stage study.Celcuity CELC -18% after raises $56M capital via equity offering.Purple Innovation PRPL -12% after lowering Q2 guidance due to production challenge.ReSha...
MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the pricing of its underwritten public offering of 2,25...
MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it has commenced an underwritten public offering of ...
MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two new senior executives to its clinical ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...